Carrot raises $25m for tech-enabled smoking cessation program

Digital health company Carrot said today that it raised $25 million to commercialize its tech-enabled Pivot smoking cessation program.

The round was led by Johnson & Johnson‘s (NYSE:JNJ) strategic venture capital arm, JJDC. New York Life Ventures and existing investors Khosla Ventures, Marc Benioff, founder Dr. David Utley and R7 Partners also contributed to the financing round.

The Redwood City, Calif.-based company’s platform combines an FDA-cleared carbon monoxide breath sensor, a smartphone app, digital coaching and pharmacotherapy to help users quit smoking. Carrot plans to partner with self-insured employers and health plans to bring Pivot to market.

Crediting Pivot’s novel approach, Carrot touted that its program yields much higher enrollment rates compared to the national average for employer-delivered smoking cessation programs.

“Quitting smoking greatly reduces chances of developing smoking-related diseases, yet successful quit attempts require a multi-disciplinary approach,” Utley said in prepared remarks. “Given Johnson & Johnson’s expertise across its medical device, consumer health and wellness, and pharmaceutical sectors, we are excited to have JJDC lead this round as we believe it takes a concerted healthcare approach to address the consequences of smoking on a global scale. We’re also pleased to have the funding of New York Life Ventures and the continued confidence of our existing investors. Their support furthers our mission to help millions of people to quit smoking.”

“Carrot is a strong example of those companies that are driving exciting innovations at the intersection of digital health and life insurance,” Tim Del Bello, director of investments at New York Life Ventures, added. “These technologies have the potential to play a meaningful role in the future of the life insurance industry.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW